key: cord-0802642-z4h40xvm
authors: Tang, Cynthia Y.; Wang, Yang; McElroy, Jane A.; Li, Tao; Hammer, Richard; Ritter, Detlef; Lidl, Grace M.; Webby, Richard; Hang, Jun; Wan, Xiu‐Feng
title: Reinfection with two genetically distinct SARS‐CoV‐2 viruses within 19 days
date: 2021-07-05
journal: J Med Virol
DOI: 10.1002/jmv.27154
sha: d108a54391c80f0fc44766d451a5895137c8bab3
doc_id: 802642
cord_uid: z4h40xvm

Increasing detection of reinfections and waning neutralizing antibody (Nab) titers as early as 23 days following initial infection raise concerns for herd immunity and the durability of vaccine efficacy. This article is protected by copyright. All rights reserved.

To The Editor, Increasing detection of reinfections and waning neutralizing antibody (Nab) titers as early as 23 days following initial infection 1 raises concerns for herd immunity and the durability of vaccine efficacy. 2, 3 Since the first reported reinfection case in August 2020, 4 published investigative criteria for suspected SARS-CoV-2 reinfections. 6 These criteria included any individuals testing positive ≥90 days after their first laboratory-confirmed SARS-CoV-2 infection or symptomatic individuals testing positive 45-89 days after initial infection with paired respiratory specimens. 6 Here, we describe a patient infected with two genetically distinct SARS-CoV-2 strains detected 19 days apart, indicating that reinfection can occur within a short period. This patient was a female in her 20 s with asthma, obesity, anxiety, and depression, who reported cough, chills, exertional dyspnea, sore throat, dizziness, rhinorrhea, and fever during her initial COVID-19 diagnosis in March 2020. She tested positive 1 day after symptom onset and was instructed to self-isolate at home. Nineteen days following her initial positive test, she returned for another COVID-19 test due to return-to-work requirements. Despite her symptoms waning to encompass only productive cough and fatigue, she tested COVID-19 positive again. She continued to experience persistent cough, fatigue, and dyspnea until 55 days after her initial positive test.

Phylogenetic analyses showed that the two samples con- This report is limited by the unavailability of sera samples to study Nab titers and lack of information regarding the patient's potential contacts with others during the 2-week isolation period. Nevertheless, this case showed a patient who unknowingly became reinfected with two genetically distinct viruses within 19 days and may have still been infectious after the CDCrecommended 10 day isolation period. 9 Additionally, the CDC has encouraged symptom-based strategies for ending isolation rather than viral retesting for asymptomatic individuals or for individuals without new symptoms during 90 days after illness onset due to findings that detectable but noninfectious SARS-CoV-2 RNA can persist in respiratory samples. 9 Larger studies are necessary to test whether the prevalence of reinfection within a short period is high, as shown in this case; if yes, this may pose a challenge of infection control, especially as variants of concern continue to emerge and immune evasion increases despite vaccination efforts.

Reinfections are likely underreported due to lack of multiple sample collections and sequencing from the same individuals. A pressing question remains of whether immunity developed from initial infection protects against other strains. The E484K spike mutation, present in the B.1.351 and P.1 variants of concern, has raised fears over their potential to impact immune escape and reinfection. 10 With the mass rollout of COVID-19 vaccinations, other urgent unknowns include the true occurrence of reinfection, the health impact of subsequent infections, and the duration of immunity generated from infections and vaccinations. Expanding sequencing and surveillance of COVID-19 reinfections will help address many of these questions. 

The authors declare that there are no conflict of interests.

Xiu-Feng Wan and Cynthia Y. Tang conceived this study, designed the analysis, and wrote the paper. Tao Li, Yang Wang, and Cynthia Y. 

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Reinfection with SARS-CoV-2: Implications for Vaccines

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR)

Panel for detection of severe acute respiratory syndrome coronavirus 2

Rapid high throughput whole genome sequencing of SARS-CoV-2 by using one-step RT-PCR amplification with integrated microfluidic system and next-gen sequencing

Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation

Interim guidance on duration of isolation and precautions for adults with COVID-19